{"summary":"With over 8 years of experience in regulatory affairs CMC, I am passionate about supporting the development and global commercialization of innovative cell and gene therapies that can transform patients' lives. My core competencies include developing and implementing successful CMC strategies, preparing and filing global regulatory submissions, and managing and facilitating agency interactions. I am currently an Associate Director, Global Regulatory Affairs CMC Cell Therapy at Bristol Myers Squibb, where I work with a diverse and collaborative team of experts to advance BMS's pipeline of cell and gene therapies.\n\nIn my current role, I leverage my skills in cell biology, protein purification to support the CMC aspects of BMS's cell and gene therapy programs, including CAR-T and gene editing products. I am responsible for preparing and filing CMC submissions (including initial IND\/IMPD, BLA, post approval variations), as well as responding to CMC questions from global health authorities. I also coordinate and provide strategic input for agency meetings and interactions, ensuring that BMS's CMC positions are aligned with the regulatory requirements and expectations. Prior to joining BMS, I supported the global commercialization of Daiichi Sankyo's ADC pipeline, primarily focused on datopotamab deruxtecan, a novel antibody-drug conjugate for the treatment of various cancers.","lastName":"Campagna","objectUrn":"urn:li:member:224970730","geoRegion":"New York City Metropolitan Area","fullName":"Matt Campagna","firstName":"Matt","currentPositions":[{"companyName":"Bristol Myers Squibb","description":"Supporting development and global commercialization for BMS\u2019s pipeline of Cell and Gene Therapies","title":"Associate Director, Global Regulatory Affairs CMC Cell Therapy","companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"geographicArea":"NJ","country":"United States","city":"Lawrence Township","postalCode":"08648","line1":"3401 Princeton Pike"},"website":"http:\/\/www.bms.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/bristol-myers-squibb\/","industry":"Pharmaceutical Manufacturing"},"companyUrn":"urn:li:fs_salesCompany:1773","tenureAtCompany":{"numYears":1,"numMonths":10},"startedOn":{"month":8,"year":2022}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAA1ox-oBEHK4ALMUmrokyYxwHN9unXTqxjI,NAME_SEARCH,nMg0)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1587696534352?e=1723075200&v=beta&t=8DkbHp-yeIV6PdXDZwuBeMOl4xTAyTAL9VHoVCTM3cg","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1587696534330?e=1723075200&v=beta&t=M0Ab3WdztsEQSorQ77gwqS-_930I20Mbe52ZS7RvzZo","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1587696534376?e=1723075200&v=beta&t=eEhRejN1vzMJ0GrUf_iOGspc_GNEd_XnYgsZWoW07SA","height":400},{"width":598,"fileIdentifyingUrlPathSegment":"800_800\/0\/1587696534404?e=1723075200&v=beta&t=W9XcerOwb5xwQ7fR4dXlCRZNsONIbYNr2dDmicLvk2c","height":598}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C5603AQGHycL4W8qoaA\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Biotechnology Research","educations":[{"school":"urn:li:fs_salesSchool:3528","degree":"Master of Science - M.Sc","schoolName":"The Johns Hopkins University","schoolUrn":"urn:li:fs_salesSchool:3528","eduId":604072321},{"degree":"Bachelor of Science (B.S.)","schoolUrn":"urn:li:fs_salesSchool:3657","eduId":140148050,"school":"urn:li:fs_salesSchool:3657","fieldsOfStudy":["Cell Biology"],"schoolName":"Penn State University"}],"skills":[{"numOfEndorsement":0,"name":"Attention to Detail"},{"numOfEndorsement":0,"name":"Organization Skills"},{"numOfEndorsement":0,"name":"Problem Solving"},{"numOfEndorsement":0,"name":"Computer Literacy"},{"numOfEndorsement":0,"name":"Interpersonal Skills"},{"numOfEndorsement":0,"name":"Electronic Submissions"},{"numOfEndorsement":0,"name":"Timelines"},{"numOfEndorsement":0,"name":"Common Technical Document (CTD)"},{"numOfEndorsement":0,"name":"Biologics"},{"numOfEndorsement":1,"name":"cGMP practices"},{"numOfEndorsement":0,"name":"Analytical Method Validation"},{"numOfEndorsement":0,"name":"Bioassay"},{"numOfEndorsement":9,"name":"Drug Discovery"},{"numOfEndorsement":11,"name":"High Throughput Screening"},{"numOfEndorsement":10,"name":"Western Blotting"},{"numOfEndorsement":9,"name":"qPCR"},{"numOfEndorsement":8,"name":"Mammalian Cell Culture"},{"numOfEndorsement":7,"name":"Protein Purification"},{"numOfEndorsement":3,"name":"Flow Cytometry"},{"numOfEndorsement":3,"name":"Transfection"},{"numOfEndorsement":2,"name":"RNA isolation"},{"numOfEndorsement":2,"name":"DNA extraction"},{"numOfEndorsement":0,"name":"Laboratory Information Management System (LIMS)"},{"numOfEndorsement":0,"name":"RNA extraction"},{"numOfEndorsement":0,"name":"Liquid handling"},{"numOfEndorsement":3,"name":"Cell Biology"}],"numOfConnections":379,"patents":[],"headline":"Associate Director @ Bristol Myers Squibb | Regulatory Affairs CMC","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/campagnam","organizations":[],"location":"New York City Metropolitan Area","publications":[{"publishedOn":{"month":6,"year":2013},"description":"Full list of contributors in publication.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23576513","name":"Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.","publisher":"Journal of Virology","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA1ox-oBEHK4ALMUmrokyYxwHN9unXTqxjI,NAME_SEARCH,nMg0)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAyZbmcBfQrHKMAHEwpp_uQ9OqBESfK3xOg,NAME_SEARCH,py9c)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAJ_hmUBESL0L87PT-RGq5rw0Z0hAS628MA,NAME_SEARCH,vc5Z)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAEvwAsBAe20NMjreUp4TlCfCW1YxE8JTTs, , )"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAH65K4BS_IiMmyy7kwIzpteNKoZS-V11Rg,NAME_SEARCH,Zm2N)"}]},{"publishedOn":{"month":9,"year":2013},"description":"Contributing author, full list in publication.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24068929","name":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes.","publisher":"PLoS Pathogens","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAyZbmcBfQrHKMAHEwpp_uQ9OqBESfK3xOg,NAME_SEARCH,py9c)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA1ox-oBEHK4ALMUmrokyYxwHN9unXTqxjI,NAME_SEARCH,nMg0)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAH65K4BS_IiMmyy7kwIzpteNKoZS-V11Rg,NAME_SEARCH,Zm2N)"}]}],"positions":null,"posts":[{"createdAt":1714156560000,"insightId":"d55f85d3-39d5-4aca-b118-2d98453c43ff","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQEuC74dk2bqDg\/articleshare-shrink_800\/0\/1714154937227?e=1717977600&v=beta&t=OG-J0hFoEBXriIgnLHAmUMRGNeqXZb2Rw8e3ofAqV8M","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQEuC74dk2bqDg\/articleshare-shrink_800\/0\/1714154937227?e=1717977600&v=beta&t=OG-J0hFoEBXriIgnLHAmUMRGNeqXZb2Rw8e3ofAqV8M"}]},"description":"Are you looking to work for a forward-thinking organization invested in best practices and scalability? We aim to do our best as stewards of our software. Whether it's implementing microservices, end-to-end testing, or cloud first design, we're always...","resolvedUrl":"https:\/\/metrum-research-group.breezy.hr\/p\/34b57ebc03dd-junior-backend-developer?state=published","title":"Junior Backend Developer at Metrum Research Group"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":4}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7189693883235119104","threadUrn":"urn:li:activity:7189693883235119104","reactionsCount":4,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7189693882551410691","message":{"attributes":[{"start":155,"length":22,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:350023"}}}],"text":"Do I know any Junior Backend Developers looking for a new opportunity? If I do or you do, please let them know of this opportunity at my favorite employer Metrum Research Group  - of course happy to answer any questions I can help with."},"entityUrn":"urn:li:share:7189693882551410691"}}},{"createdAt":1712617620000,"insightId":"80c10e2f-c53d-42fb-a911-0189e1b9b9e4","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQGXhlsyo3jQkA\/feedshare-shrink_2048_1536\/0\/1712617619997?e=1720051200&v=beta&t=Z9HQKm0t7Ykkw1Q2Re2kEwoQxtDGlbllI5H4O25WeR0"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":44},{"type":"PRAISE","count":6},{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7183238940479377408","threadUrn":"urn:li:activity:7183238940479377408","reactionsCount":51,"commentsCount":3,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7183238939325943808","message":{"attributes":[{"length":22,"start":211,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:350023"}}},{"length":16,"start":238,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:8297253"}}}],"text":"Is was absolutely thrilling to talk to other interested scientists and clinicians at AACR about our efforts in QSP modeling to predict the efficacy of ADC + Tcell engager combinations. The collaboration between Metrum Research Group  and ADC Therapeutics has been an incredible opportunity to accompany ADCT's LOTIS-7 trial with our modeling projections."},"entityUrn":"urn:li:share:7183238939325943808"}}},{"createdAt":1712282760000,"insightId":"3c4d5c35-e584-48d8-a16e-d6517dd82770","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":3},{"type":"ENTERTAINMENT","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7181834484848177152","threadUrn":"urn:li:activity:7181834484848177152","reactionsCount":4,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181834484386795520","message":{"attributes":[],"text":"I can still sing along to Backslash B and I'm probably not the only one."},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4D27AQErsiGUM_jKFA\/articleshare-shrink_800\/0\/1712277908250?e=1717977600&v=beta&t=W3s6ZvaWwS4OVp3AK0urvGP4LmHjO4ehxCiZDKTVhEg","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4D27AQErsiGUM_jKFA\/articleshare-shrink_800\/0\/1712277908250?e=1717977600&v=beta&t=W3s6ZvaWwS4OVp3AK0urvGP4LmHjO4ehxCiZDKTVhEg"}]},"description":"We explore the tension between our desire to quantify our objectives and the objects of life which remain unquantifiable.","resolvedUrl":"https:\/\/open.substack.com\/pub\/lessonsinchimeristry\/p\/4-ofs-no-not-only-fans-objective?r=11p4o&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true","title":"#4 - OFs - No not Only Fans; Objective Functions"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181815074582323200","message":{"attributes":[{"length":10,"start":124,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:31888322"}}},{"length":11,"start":136,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:2971073"}}},{"length":12,"start":149,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:225865579"}}},{"length":12,"start":163,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:167814457"}}},{"length":15,"start":177,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:305345778"}}},{"length":9,"start":194,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:26919611"}}},{"length":15,"start":205,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:11712257"}}},{"length":10,"start":306,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:69244073"}}},{"length":11,"start":357,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:16655"}}}],"text":"Discussions on objective functions and the tension between the measurable and the unquantifiable.  Back to grad school with Erik Allen, Joel Moxley, Ryan Bennett, Tyler Martin, Mark Styczynski, Ken Beers, Daniel Pregibon making appearances.  So does bbhedge, ever so slightly.  And how this dovetails with Adam Grant's excellent book Give and Take.  Thanks Rohit Khare"},"entityUrn":"urn:li:share:7181815074582323200"},"entityUrn":"urn:li:share:7181834484386795520"}}},{"createdAt":1712123280000,"insightId":"d11b1ce7-fca4-44fb-8b91-317d08cf1367","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":11}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7181165747623075840","threadUrn":"urn:li:activity:7181165747623075840","reactionsCount":11,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181165747132321793","message":{"attributes":[],"text":"Going to AACR next week?  Interested in how systems modeling can be used to predict the efficacy of ADC + Tcell engager combinations? Come by Poster 19 this Sunday (1:30-5pm) and I'll tell you all about it!  "},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D5622AQFs9krQTA9pDA\/feedshare-shrink_2048_1536\/0\/1712065324031?e=1720051200&v=beta&t=e9NvusecFb0TBv0H9qfzso1_mqcxbCUPBbN5dOnps68"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7180922439390912512","message":{"attributes":[{"start":1237,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:aacr2024"}}},{"start":1247,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancertherapy"}}},{"start":1262,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:combinationtherapy"}}},{"start":1282,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:aacrannualmeeting"}}},{"start":1301,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:postersession"}}},{"start":1316,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:qsp"}}}],"text":"Our poster at the AACR Annual Meeting is your chance to explore advances in novel cancer therapy combinations alongside MetrumRG modeling and simulation innovators. QSP model simulations were used to predict anti-tumor efficacy and guide dosing of the antibody-drug conjugate Loncastuximab tesirine combined with T cell-dependent bispecific antibodies, Mosunetuzumab or Glofitamab for the treatment of B-cell malignancies. \n\nTargeted Treatments: Lonca targets CD19 on B cells, while Mosun and Glofit redirect T cells to malignant B-cell by simultaneously engaging CD20 on B cells and CD3 on\u00a0 T cells. \n\nResearchers: Yuezhe Li, A Katharina Wilkins, and Tim Knab from MetrumRG, along with J.P. Boni from ADC Therapeutics, conducted this innovative research.\n\nModel Predictions: Learn how our PKPD QSP model, presented by Katharina Wilkins, forecasts improved tumor growth inhibition with Lonca + Mosun\/Glofit combination therapy compared to either monotherapy.\n\nClinical Insights: Explore how these findings can impact treatment strategies for relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL) in ongoing clinical trials.\n\nDate: Sunday, April 7, 2024\nTime: 1:30 PM - 5:00 PM\nLocation: Poster Section 36\nAbstract Number: 19\n\n#AACR2024 #CancerTherapy #CombinationTherapy #AACRAnnualMeeting #PosterSession #QSP"},"entityUrn":"urn:li:share:7180922439390912512"},"entityUrn":"urn:li:share:7181165747132321793"}}},{"createdAt":1716897960000,"insightId":"bb632685-bddc-4c75-b4e3-334e1104fa33","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":3}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7201174628122202114,7201192018855821312)","threadUrn":"urn:li:activity:7201174628122202114","reactionsCount":3,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"I walked into my first job out of grad school a cool 5months and very visibly pregnant. It was a start up environment and I had only signed a temporary contract to see if it was a fit. On that first day, I told them I was already a working mom and not to sweat. Before my contract was ending and long before the baby came, they asked me to sign a permanent contract and I worked there for 4 years and one more pregnancy afterwards. I guess I was sneaky going into it but also felt like I didn't make them commit to more than 3 months anyway. It remains a reality that we'll have to juggle this topic. MA is a good place to be in but it's more important to interview and accept positions with the right people."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7201174628122202114"}}},{"createdAt":1715195940000,"insightId":"ae317296-6ed9-4081-8e80-37a1f3f0f472","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7189329959721623552,7194053223597379585)","threadUrn":"urn:li:activity:7189329959721623552","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Is that a Monstera? My office looks like this thanks to my plant-crazy teenage kid :-) It's really nice to have living plants around us! "},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7189329959721623552"}}},{"createdAt":1715195640000,"insightId":"739a01b2-e439-4c59-a868-5d6078d2f023","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"EMPATHY","count":1},{"type":"PRAISE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7193254111515938816,7194052038182256643)","threadUrn":"urn:li:activity:7193254111515938816","reactionsCount":2,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":17,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:227431650"}}}],"text":"So lucky to have Kiersten Utsey on my team! "},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7193254111515938816"}}},{"createdAt":1712851320000,"insightId":"8ed21670-58d2-46c7-af44-227104c77a5a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7183238940479377408,7184219167972016128)","threadUrn":"urn:li:activity:7183238940479377408","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:22560595"}}}],"text":"Joseph Boni thank you for giving us this great opportunity! We can't wait to learn how LOTIS-7 turns out!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7183238940479377408"}}},{"createdAt":1712544000000,"insightId":"9b70b725-e01e-4c7b-b90e-245aa5929c1a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7182890201927626752,7182930203965300736)","threadUrn":"urn:li:activity:7182890201927626752","reactionsCount":2,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Yes I'm around!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7182890201927626752"}}},{"createdAt":1712282700000,"insightId":"c9e15552-4efe-47ec-9627-8527e5ca14bc","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7181815075685449729,7181834379101380608)","threadUrn":"urn:li:activity:7181815075685449729","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Oh most bestest memory ever (no matter the OF) - Backlash B! In my current world we look for our 'Why?' - but the concept is the same. Great post. Fond memories. "},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7181815075685449729"}}},{"createdAt":1712148360000,"insightId":"d6b3e9c3-9548-43c8-b1c7-30c73920e315","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7181252699256975360,7181270774664548352)","threadUrn":"urn:li:activity:7181252699256975360","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"What a fun shiny app! \n"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7181252699256975360"}}},{"createdAt":1711675260000,"insightId":"64d435ff-d6ea-4195-b1d8-33b2fb163a5a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7179117927353266177,7179286631126814720)","threadUrn":"urn:li:ugcPost:7179117927353266177","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Rob! Exciting news!\n"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7179117927353266177"}}},{"createdAt":1710887520000,"insightId":"6d33cf0f-48ba-4769-a42f-6d78ba14a92a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7171157765741133825,7175982391646146561)","threadUrn":"urn:li:ugcPost:7171157765741133825","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Gratuliere!\n"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171157765741133825"}}},{"createdAt":1710606420000,"insightId":"f37b0279-568f-490b-a0ac-825a8588e039","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7171875495255461889,7174803501150044160)","threadUrn":"urn:li:ugcPost:7171875495255461889","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Chris"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171875495255461889"}}}]}